Catalyst Funds Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Catalyst Funds Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$448K	Buy	+17,293	New	+$444K	0.08%	270

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Catalyst Funds Management's DMRA Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 17,293 shares worth $448K. The stake represents 0.08% of the portfolio and ranks #270 among its holdings.

65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Catalyst Funds Management held 17,293 shares of Damora Therapeutics, Inc. Ordinary Shares worth $448K as of Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares was a new Catalyst Funds Management position in Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares made up 0.08% of Catalyst Funds Management's portfolio in Q1 2026, its #270 holding.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.